Company Directory
PharmiWeb's Pharma Company Directory is a comprehensive and searchable listing of organisations within the Pharma, Biotech & Life Sciences sector. Use it to find partner organisations, suppliers, or even a company to work for!
As an organisation, a basic listing is FREE, and can raise your profile in the industry, making you visible to thousands of monthly site visitors.
To add your organisation to the directory, simply register as a contributor and add your organisation's details.
Note that we only accept contributions relating to the Pharma industry and that it will typically take 2 working days to approve (or otherwise) your details. Once approved, you will also be able to contribute press releases and event details to our site. Our desision is final.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer cell division.
Novotech is internationally recognized as the leading regional full-service Contract Research Organization (CRO). Novotech has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotechnology companies.
Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy.
"NuCana" is derived from "New Cancer Agents” and “Nucleotide Analogs”. It represents our goal of inventing, developing and commercialising truly novel, transformational medicines, as well as the proprietary medicinal chemistry platform upon which they are based. Our medicines are completely new cancer treatments.
Nucleus Network is Australia’s largest Phase 1 clinical research organization and the only Phase 1 specialist globally with facilities in the USA and Australia. Since our establishment in 2004, Nucleus Network has conducted well over 1000 Phase 1 clinical trials for Biotechnology and Pharmaceutical Companies from across the globe.
By transforming recent scientific breakthroughs in axonal degeneration and neuroimmune regulation into neuroprotective medicines, we aim to offer renewed hope for those affected by serious neurological diseases.
Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for a broad range of diseases.
A biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through our collaboration with pioneer scientists in the field.
OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.
ONK Therapeutics is dedicated to optimizing a next generation of off-the-shelf, dual-targeted NK cell therapies for patients with hematological malignancies and solid tumors.
OSP Healthcare is an independent creative medical communications agency with a global reach. Having delivered more than 1000 projects in almost three decades for health-focused companies and organisations, our code-compliant team is well versed when it comes to the healthcare, pharma and biotech sectors.
OXGENE™ finds solutions to seemingly impossible problems. Our unique combination of precision engineering and breakthrough science, together with advanced robotics and bioinformatics, accelerates the rational design, discovery and manufacture of cell and gene therapies.
At Obsidian, we are pioneering engineered cell and gene therapies to deliver transformative outcomes for patients.
ObvioHealth is a Virtual Research Organization (VRO) leading the long overdue digitization of health innovation. We launched in 2017, leveraging technological innovation to tackle the inefficiencies in the trial process. But we knew then and now, that success would come from the fusion of experienced clinical researchers and pioneering health technologists.
Ochre Health is a network of health professionals who share a clear purpose and take a proactive approach in creating healthier communities. Together we can transform healthcare, giving you the infrastructure, support, tools and clinical autonomy needed to practice patient-centred care.
Family owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 countries and reach hundreds of thousands of patients every year. We focus on three therapeutic areas: haematology, immunotherapy and critical care.
At Omega Therapeutics, we are pioneering the discovery of epigenomic targets to develop a new class of therapeutics to fundamentally transform human medicine in the service of patients. Our objective is to become the leading digital and data-driven epigenetic medicines company.
